NORWELL, Mass., and MIAMI, Fla., March 12, 2026
The National Organization for Rare Disorders (NORD) and OpenEvidence have announced a strategic partnership aimed at expanding global access to AI-powered rare disease knowledge resources for clinicians, patients, and caregivers. The collaboration will combine advanced artificial intelligence technology with expert medical review to build a large and continuously updated library of rare disease summaries designed to improve diagnosis, treatment awareness, and patient education.
Through the partnership, the organizations plan to develop more than 3,000 rare disease knowledge summaries, available in both clinician-focused formats and patient-friendly explanations, helping bridge critical information gaps for the millions of individuals affected by rare diseases worldwide. By integrating AI-driven analysis of biomedical literature with expert validation from specialists within the NORD Rare Disease Centers of Excellence Network, the initiative aims to deliver trusted, accessible, and up-to-date information that supports better clinical decision-making and empowers patients navigating complex rare disease journeys.
Expanding Access to Rare Disease Knowledge
Rare diseases collectively affect over 30 million people in the United States and more than 300 million individuals globally, yet many conditions remain poorly understood and difficult to diagnose. Patients often face years of uncertainty before receiving a correct diagnosis, and even after diagnosis, families and healthcare professionals must navigate a fragmented landscape of medical research and clinical information.
The new partnership seeks to address these challenges by creating a comprehensive digital library of rare disease resources powered by artificial intelligence. The platform will synthesize data from thousands of peer-reviewed scientific publications and clinical studies, translating complex biomedical research into structured summaries that clinicians can easily access during patient care.
Advertisement
Experts recommended by NORD will review the clinician-focused content to ensure clinical accuracy, real-world relevance, and alignment with the latest rare disease research and treatment guidelines. By combining AI-based literature synthesis with human expert validation, the collaboration aims to scale the production of reliable rare disease information while maintaining the highest standards of medical accuracy.
AI Platform Integrates Clinical Insights with Patient Education
The new rare disease knowledge resources will be integrated directly into the OpenEvidence medical AI platform, allowing physicians to access relevant summaries automatically when clinical questions arise. The system is designed to analyze the latest biomedical literature and present key insights in a concise and clinically actionable format, helping physicians navigate complex rare disease research without requiring extensive manual literature review. In addition to clinician-focused materials, the partnership will also create patient-friendly educational content designed to make complex medical information more understandable for patients and caregivers.
These materials will be distributed through the NORD Rare Disease Database, enabling families worldwide to access trusted educational resources that support informed healthcare decisions. The initiative reflects a growing recognition that combining advanced AI capabilities with expert clinical oversight can dramatically expand the availability of high-quality medical knowledge, particularly in fields such as rare diseases where research is rapidly evolving and often difficult to interpret.
Strengthening Rare Disease Diagnosis and Care
The collaboration between NORD and OpenEvidence aims to accelerate the recognition and diagnosis of rare diseases while improving communication between clinicians and patients. By providing clinicians with evidence-based summaries that are updated monthly, the platform will ensure that healthcare professionals have access to the most current information about rare disease mechanisms, diagnostic pathways, and emerging treatments. At the same time, the patient-friendly resources will help individuals and families better understand their conditions, enabling more informed conversations with healthcare providers and stronger engagement in care decisions.
Experts involved in the initiative believe the project demonstrates how artificial intelligence can help organize the vast and fragmented body of biomedical knowledge associated with rare diseases, transforming complex research data into practical tools that support both clinical care and patient empowerment. As AI technologies continue to evolve, collaborations such as this one highlight the potential for digital health innovation to expand access to medical knowledge and improve outcomes for underserved patient populations, including those affected by rare and complex diseases.
Source: National Organization for Rare Disorders (NORD®) press release
